B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
- PMID: 10581077
- DOI: 10.1038/70932
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Abstract
The B7 family members B7-1 and B7-2 interact with CD28 and constitute an essential T-cell co-stimulatory pathway in the initiation of antigen-specific humoral and cell-mediated immune response. Here, we describe a third member of the B7 family, called B7-H1 that does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). Ligation of B7-H1 co-stimulated T-cell responses to polyclonal stimuli and allogeneic antigens, and preferentially stimulated the production of interleukin-10. Interleukin-2, although produced in small amounts, was required for the effect of B7-H1 co-stimulation. Our studies thus define a previously unknown co-stimulatory molecule that may be involved in the negative regulation of cell-mediated immune responses.
Comment in
-
T-cell stimulation: an abundance of B7s.Nat Med. 1999 Dec;5(12):1345-6. doi: 10.1038/70905. Nat Med. 1999. PMID: 10581066 No abstract available.
Similar articles
-
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.Nat Immunol. 2001 Mar;2(3):269-74. doi: 10.1038/85339. Nat Immunol. 2001. PMID: 11224528
-
T-cell co-stimulation through B7RP-1 and ICOS.Nature. 1999 Dec 16;402(6763):827-32. doi: 10.1038/45582. Nature. 1999. PMID: 10617205
-
T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.Cancer Res. 2001 Mar 1;61(5):1976-82. Cancer Res. 2001. PMID: 11280755
-
[Lymphocyte coreceptors].Med Sci (Paris). 2006 Dec;22(12):1069-74. doi: 10.1051/medsci/200622121069. Med Sci (Paris). 2006. PMID: 17156728 Review. French.
-
The balance of immune responses: costimulation verse coinhibition.J Mol Med (Berl). 2005 Mar;83(3):193-202. doi: 10.1007/s00109-004-0617-1. Epub 2005 Jan 4. J Mol Med (Berl). 2005. PMID: 15630593 Review.
Cited by
-
Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma.Diagnostics (Basel). 2020 Jun 11;10(6):394. doi: 10.3390/diagnostics10060394. Diagnostics (Basel). 2020. PMID: 32545177 Free PMC article.
-
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.World J Gastroenterol. 2016 Oct 7;22(37):8389-8397. doi: 10.3748/wjg.v22.i37.8389. World J Gastroenterol. 2016. PMID: 27729745 Free PMC article.
-
T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors.Int J Mol Sci. 2020 Oct 8;21(19):7424. doi: 10.3390/ijms21197424. Int J Mol Sci. 2020. PMID: 33050044 Free PMC article. Review.
-
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?Drugs. 2016 Jun;76(9):925-45. doi: 10.1007/s40265-016-0588-x. Drugs. 2016. PMID: 27229745 Review.
-
Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.J Adv Res. 2022 Sep;40:109-124. doi: 10.1016/j.jare.2021.12.005. Epub 2021 Dec 21. J Adv Res. 2022. PMID: 36100320 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
